BUSINESS OVERVIEW 6 Visual Function Evolution: Trends of Improved Acuity at 2.5 Years 48 weeks of follow-up). As described in the following table, we of Follow-up continued to observe a greater magnitude of treatment effect In December 2017, we reported results in 14 subjects after when the disease duration was less than two years as compared 2.5 years of follow-up (one subject withdrew its consent after to a disease duration that was greater than two years. ETDRS letters (LogMAR) Visual Acuity change from baseline 1.0 year 1.5 year 2.0 years 2.5 years Δ Treated Eye vs Untreated Eye All subjects +3 letters +8 letters +0 letters +7 letters (n = 14) (-0.06) (-0.16) (-0.00) (-0.14) Subjects with +17 letters +20 letters +14 letters +15 letters ≤ 2y disease (-0.34) (-0.40) (-0.28) (-0.30) duration (n = 5)* Note (*) Excludes “hand motion” subjects, in accordance with the Phase I I I protocol. In the following chart, five letters correspond to one line on the ETDRS chart. Therefore, a difference of 15 letters is equivalent to three lines on the ETDRS chart, the widely recognized standard of clinically significant improvement. Evolution of visual acuity in the treated eye vs. untreated eye at 2.5 years of follow-up in subjects with vision loss duration ≤ 2 years and Baseline LogMAR ≤ 2.79 (n = 5) (i.e., excludes “hand motion” subjects, in accordance with the Phase I I I protocol) GENSIGHT BIOLOGICS – 2017 Registration Document– 75